As he watches COVID-19 numbers climb in New Jersey, Steven K. Libutti reviews all the things he had learned last spring, when the pandemic first slammed the state.
November is Lung Cancer Awareness Month, a time to turn our attention to an issue that already warrants our focus year-round.
A cancer pioneer, Helene G. Brown had coined the name for her peculiar subspecialty: political oncology.
Opdivo (nivolumab) in combination with Yervoy (ipilimumab) received FDA approval for the first-line treatment of adults with malignant pleural mesothelioma that cannot be removed by surgery.
Regeneron has submitted a request to FDA for Emergency Use Authorization approval for the
FDA has issued draft guidance encouraging the inclusion of premenopausal women in breast cancer clinical trials that investigate the efficacy of hormonal drug and biological products.
In a new clinical trial, City of Hope is investigating a treatment for cancer patients with COVID-19 by repurposing leflunomide, an anti-inflammatory drug for rheumatoid arthritis, which is inexpensive and has few serious side effects.
A novel cancer therapy studied and developed at the Medical College of Wisconsin with promising clinical outcomes is leading to a larger phase II trial to improve on the current standard of care.
Researchers at MD Anderson Cancer Center have identified molecular and cellular characteristics of anti-CD19 CAR T cell infusion products associated with how patients with large B-cell lymphoma respond to treatment and develop side effects.
A study from researchers at MD Anderson Cancer Center indicates that mutations found in cancers do not accumulate randomly, but are found in distinct patterns that vary based on the three-dimensional organization of the genome in the cell as well as the underlying factors causing the mutations.
